Obsessive-Compulsive Disorder (OCD)

Obsessive-Compulsive Disorder (OCD) is characterized by repeated, unwanted thoughts (obsessions) and/or repetitive behaviors (compulsions) that cause significant distress and functional impairment. It affects approximately 2–3% of the general population and is among the more treatment-resistant psychiatric disorders. Only about 40–60% of patients respond adequately to the combination of SSRIs and Cognitive Behavioural Therapy with Exposure and Response Prevention (CBT/ERP).

The FDA granted De Novo clearance for rTMS in OCD in 2018. Learn more about how rTMS works.

Why it matters

Approximately 25–40% of patients with OCD remain treatment-resistant even after multiple medication trials and high-intensity psychotherapy. Therapeutic alternatives are limited: surgical neuromodulation such as DBS, high-dose clomipramine, or augmentation strategies. rTMS, particularly Deep TMS (dTMS), enters this space as a non-invasive intermediate option, clinically approved and supported by evidence of effectiveness. Learn more about cost and procedure for OCD.

Mechanism

• Neurobiological basis of OCD: Dysfunction of the cortico-striato-thalamo-cortical (CSTC) circuit, with hyperactivity of the orbitofrontal cortex (OFC) and caudate nucleus, creating a “stuck” loop of repetitive thought and behavior.
• rTMS target in OCD: Low-frequency (LF, 1 Hz) inhibition of the right DLPFC or supplementary motor area (SMA) to regulate compulsive motor drive. As with every protocol, individualized treatment through motor threshold measurement is essential. An alternative approach is deep TMS targeting of the OFC/ACC.
• Symptom provocation: Activating OCD circuits a few minutes before TMS can enhance effectiveness by using the activated state for targeted neuromodulation and plasticity.

Clinical significance

The pivotal randomized controlled trial that led to FDA clearance, Carmi et al. 2019, showed a statistically significant reduction in Y-BOCS score of approximately 38.1% in the active dTMS group with symptom provocation compared with placebo. Meta-analyses across rTMS/dTMS protocols in OCD show a moderate to strong effect, with effect sizes around 0.6–0.8. Response appears better in patients with a dominant “symmetry/ordering” dimension and weaker in those with prominent “hoarding” symptoms. See more frequently asked questions about rTMS in OCD.

Explicit relations (Entity Graph)

• OCD neurobiological substrate: CSTC circuit (OFC → caudate → thalamus → PFC).
• Main rTMS target in OCD: right DLPFC (LF, 1 Hz) or SMA.
• dTMS target in OCD: OFC/ACC through the H7 coil.
• rTMS/dTMS for OCD received FDA De Novo clearance in 2018.
• Symptom provocation enhances dTMS effectiveness in OCD.
• rTMS/dTMS in OCD has an effect size of approximately 0.6–0.8 in meta-analyses.
• OCD treatment resistance: approximately 25–40% non-response to SSRIs + CBT/ERP.
• Alternative treatments for OCD include DBS, capsulotomy, intravenous clomipramine, and ketamine.

References

1. Carmi L, Tendler A, Bystritsky A, et al. (2019). Efficacy and safety of deep transcranial magnetic stimulation for obsessive-compulsive disorder: a prospective multicenter randomized double-blind placebo-controlled trial. American Journal of Psychiatry.
2. Rehn S, Eslick GD, Brakoulias V. (2018). A meta-analysis of the effectiveness of different cortical targets used in repetitive transcranial magnetic stimulation (rTMS) for the treatment of obsessive-compulsive disorder (OCD). Psychiatric Quarterly.
3. Greenberg BD, Ziemann U, Cora-Locatelli G, et al. (2000). Altered cortical excitability in obsessive-compulsive disorder. Neurology.